Gilead Sciences Inc
0.17 (0.22%)


Draw Mode:

Volume 5,625
Bid Price 77.42
Ask Price 77.52
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Gilead Sciences Inc GILD NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.17 0.22% 77.48 08:00:12
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
151 5,625 - 57.165 - 89.74
Last Trade Time Type Quantity Stock Price Currency
08:02:26 1 $ 77.31 USD

Gilead Sciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 96.63B 1.25B 1.26B $ 27.28B $ 4.70B 3.65 21.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ 2.92 3.88% 03/14/23 315.52k 0.70%

more financials information »

Gilead Sciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No GILD Message Board. Create One! See More Posts on GILD Message Board See More Message Board Posts

Historical GILD Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week78.56581.2776.52578.728,263,888-1.08-1.38%
1 Month84.7385.4976.52580.186,078,600-7.25-8.56%
3 Months85.2588.2976.52583.256,285,055-7.77-9.11%
6 Months65.4189.7461.44579.787,390,74712.0718.45%
1 Year59.3489.7457.16570.947,463,02618.1430.57%
3 Years79.5089.7456.5669.348,819,159-2.02-2.54%
5 Years77.3889.7456.5669.198,434,9910.100.13%

Gilead Sciences Description

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology.